浙江泰林生物技术股份有限公司的主营业务是生命科学领域微生物检测与污染控制、创新药物研发生 产、过程分析和阻遏防护等产品的研发、生产和推广应用，为生物医药、医疗保健、食品饮料、环境保 护等行业提供具有高质量的产品和解决方案。公司的主要产品是集菌仪、集菌培养器、微生物检验仪、 微孔滤膜、酶底物法大肠菌群检测系统、酶底物智能培养计数系统、全自动两虫检测系统、生物指示 剂、生物指示剂抗力仪、质控菌株、隔离器、无菌传递舱、阻遏隔离器、多功能细胞处理工作站、蜂巢 培养系统（转运车+蜂巢培养箱）、无菌分装工作站、汽化过氧化氢发生器、过氧化氢雾化消毒机、全 自动菌落计数工作站、全自动无菌检查培养系统、细菌侵入测试仪、TOC分析仪、固体燃烧装置、生物 降解测试系统、真空/压力衰减测试仪、顶空氧分析仪、过滤器完整性测试仪、过氧化氢气体浓度分析 仪、水气体浓度分析仪、二氧化碳气体浓度传感器。 最新一期业绩显示，2025年一季报，公司实现营业收入6693.90万元，同比-16.33%；净利润352.82万 元，同比-39.93%，销售毛利率49.27%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13泰林生物238.08 ...

7月4日，迪瑞医疗今日收盘14.03元，下跌1.06%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到106.87倍，总市值38.26亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13迪瑞医疗106.8726.961.8538.26亿行业平均 51.0548.784.55107.12亿行业中值36.6236.522.5051.67亿1九安医疗10.2610.380.81173.21亿2英科医疗 10.4711.290.93165.45亿3新华医疗14.4313.381.1892.52亿4奥美医疗15.3215.011.5755.35亿5山东药玻 15.3915.431.77145.53亿6振德医疗15.4714.580.9856.17亿7康德莱15.7315.741.3033.89亿8维力医疗 16.4917.141.9337.60亿9九强生物16.4915.332.0281.66亿10奥泰生物16.6117.511.3452.96亿11安杰思 17.6117.812.1352.26亿12安图生物18.8317.982.42214.74亿 来源：金融界 迪瑞医疗科技股份有限公司的 ...

深圳迈瑞生物医疗电子股份有限公司的主营业务是医疗器械的研发、制造、营销及服务。公司的主要产 品是生命信息与支持类产品、体外诊断类产品、医学影像类产品、电生理与血管介入类产品、其他类产 品、其他业务。 最新一期业绩显示，2025年一季报，公司实现营业收入82.37亿元，同比-12.12%；净利润26.29亿元，同 比-16.81%，销售毛利率62.53%。 7月4日，迈瑞医疗今日收盘223.8元，上涨1.63%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到24.36倍，总市值2713.44亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均51.05倍，行业中值36.62倍，迈瑞医疗排 名第53位。 资金流向方面，7月4日，迈瑞医疗主力资金净流出1028.21万元，近5日总体呈流出状态，5日共流出 14851.39万元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13迈瑞医疗24.3623.257.032713.44亿行业平均 51.0548.784.55107.12亿行业中值36.6236.522.5051.67亿1九安医疗10.2610.380.81173.21亿2英科 ...

麦克奥迪(厦门)电气股份有限公司的主营业务是环氧绝缘件、光学显微镜、模具、医疗检测产品的生 产、销售；医疗诊断服务及能源互联网的技术研发与运营。公司的主要产品是电气产品、显微镜产品、 医疗产品及服务。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13麦克奥迪49.2750.224.3781.08亿行业平均 35.9138.713.5190.32亿行业中值38.1340.152.5847.19亿1炬华科技11.1212.171.9680.88亿2新联电子 11.6417.051.3345.46亿3正泰电器12.4712.741.14493.62亿4金杯电工12.6112.661.7472.00亿5三星医疗 13.0513.782.47311.27亿6海兴电力13.1412.191.68122.10亿7友讯达15.2913.662.5827.06亿8柘中股份 16.4381.862.0959.88亿9特变电工16.4414.870.94614.92亿10长高电新16.9717.221.7743.42亿11宏力达 17.1715.970.9435.57亿12平高电气17.6319.841.87203.00 ...

序号股票简称PE(TTM)PE(静)市净率总市值(元)8东华能源33.9033.661.34149.42亿行业平均 12.7911.501.211749.81亿行业中值29.3233.481.5955.79亿1ST新潮9.208.411.01218.30亿2中国海油 9.279.061.5912495.62亿3中国石油9.509.561.0115739.80亿4广汇能源13.6913.161.41389.76亿5中国石化 15.2213.690.826886.73亿6洲际油气22.4119.911.1297.09亿7泰山石油24.7333.303.0333.08亿9康普顿 41.3350.502.3527.59亿10广聚能源65.1870.302.4268.16亿11和顺石油86.5996.571.7128.26亿12岳阳兴长 101.1888.382.5755.79亿 来源：金融界 截至2025年一季报，共有11家机构持仓东华能源，其中其他8家、基金2家、券商1家，合计持股数 71487.21万股，持股市值68.27亿元。 东华能源股份有限公司的主营业务是公司需遵守《深圳证券交易所上市公司自律监管指引第3号 ...

最新一期业绩显示，2025年一季报，公司实现营业收入7.96亿元，同比-16.49%；净利润2565.19万元， 同比-9.35%，销售毛利率27.96%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13新里程65.5664.053.6473.51亿行业平均 41.6648.883.54163.47亿行业中值43.2658.582.7256.99亿1药明康德18.1921.523.262034.10亿2康龙化成 23.2624.233.09434.59亿3诺泰生物25.1330.494.49123.29亿4普蕊斯27.3023.372.1124.88亿5诺禾致源 28.9829.952.3358.93亿6爱尔眼科30.6731.975.211136.77亿7诺思格31.8732.562.4545.65亿8凯莱英 32.3133.831.87321.07亿9华康洁净35.1636.801.4124.58亿10通策医疗35.8736.644.36183.75亿11华厦眼科 37.9837.432.72160.44亿12阳光诺和41.3631.295.3955.52亿 7月4日，新里程今日收盘2.17元 ...

Core Viewpoint - The article discusses the significant impact of the recent alcohol ban on the liquor industry, highlighting a sharp decline in sales and profits across various segments and regions [2][3]. Industry Overview - The overall liquor industry has experienced a downturn, with a reported 18.7% decline in revenue in Shandong province during the first month of the ban. High-end product lines, such as those from leading brands like Jingzhi and Bandaojiu, saw sales drop by 35%-40%. The inventory turnover period has increased from 45 days to 120 days [3]. - In June, the first full month affected by the policy, most liquor merchants reported a sales and profit decline of over 30%-50% compared to May. Data from the China Alcoholic Drinks Association indicates that 59.7% of liquor companies experienced a decrease in profit margins in the first half of the year [3]. Consumption Patterns - There has been a noticeable reduction in consumption scenarios, particularly in dining settings and events like "Thanking Teachers" and "Graduation Banquets," with significant impacts observed in regions like Guangdong where such events have nearly ceased. Corporate group purchases have also declined, with fewer gatherings in state-owned enterprises [3]. Price and Channel Disparities - The mid-to-high-end price segments (300-800 RMB, especially above 500 RMB) have been hit hardest, with group purchase sales in Jiangsu and Shandong dropping by 60%-70%. Notable brands have seen a decrease in wholesale prices, while mid-to-low-end products in regions like Anhui experienced a 50% decline in sales [4]. - Channel performance varies, with warehouse-style retail remaining stable or slightly increasing, while high-end retail has seen a 15%-20% decline. General retail and group purchases have dropped by 30%, and high-end group purchases and business scenarios have decreased by 50% [4]. Channel Survival Challenges - Many chain liquor stores and tobacco shops are facing significant profit declines, with some businesses in Shandong and Wuhan unable to cover rent and facing potential losses and layoffs. Poor inventory turnover and declining wholesale prices have led to cautious restocking practices [4]. Management Strategies - Liquor manufacturers are advised to "actively wash away" accumulated pressures in the second quarter to prepare for future challenges. The focus should be on achieving better performance than peers rather than absolute results [5]. Historical Context and Future Outlook - Historical comparisons suggest that while the current situation is challenging, it may not be as severe as past crises, such as the plasticizer scandal and the "Eight Regulations" in 2012. The current ban is seen as a less drastic change, with corrective measures already being implemented [8]. - The article posits that the liquor sector's long-term prospects remain positive, with a belief that economic recovery will eventually lead to a resurgence in demand for liquor consumption [9]. Performance Indicators - The worst-case scenario for the liquor industry this year could involve negative growth for all companies except for Moutai. The stability of Moutai's wholesale prices and the sales performance of Wuliangye are viewed as key indicators for market confidence [9].

7月3日，新开源今日收盘17.09元，上涨1.12%，滚动市盈率PE（当前股价与前四季度每股收益总和的比 值）达到26.91倍，总市值83.07亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入3.25亿元，同比-17.69%；净利润8042.03万元， 同比-33.75%，销售毛利率44.07%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13新开源26.9123.752.2383.07亿行业平均 45.4652.833.8280.74亿行业中值41.1241.842.4143.80亿1正丹股份8.2110.483.91124.75亿2星湖科技 10.2512.671.42119.46亿3梅花生物10.5711.602.06317.80亿4嘉化能源11.0811.791.15118.86亿5聚合顺 11.4511.851.8435.60亿6万华化学14.3313.141.741713.05亿7雪峰科技14.7513.421.8089.70亿8浙江龙盛 14.9816.440.96333.79亿9宇新股份16.2814.261.0743.80亿10江南化工16.9216.951.5615 ...

7月3日，ST景峰今日收盘5.87元，下跌1.34%，滚动市盈率PE（当前股价与前四季度每股收益总和的比 值）达到36.49倍，总市值51.64亿元。 从行业市盈率排名来看，公司所处的化学制药行业市盈率平均54.72倍，行业中值33.17倍，ST景峰排名 第95位。 湖南景峰医药股份有限公司的主营业务是医药产品的研发、制造与销售。公司的主要产品是参芎葡萄糖 注射液、心脑宁胶囊（全国独家、国家医保乙类）、盐酸替罗非班注射用浓溶液、盐酸替罗非班氯化钠 注射液、注射用盐酸地尔硫卓和乐脉丸、射用培美曲塞二钠、注射用盐酸吉西他滨、盐酸伊立替康注射 液、注射用磷酸氟达拉滨、注射用奥沙利铂和来曲唑片、璃酸钠注射液（含玻璃酸钠原料药）、镇痛活 络酊（全国独家、国家医保乙类）、通迪胶囊（全国独家）和骨筋丸胶囊、妇平胶囊（全国独家）、金 鸡丸（全国独家）和儿童回春颗粒、注射用泮托拉唑钠、注射用奥美拉唑钠、注射用兰索拉唑、复方胆 通胶囊（国家医保乙类）和消炎利胆胶囊（基药、国家医保甲类）、冰栀伤痛气雾剂（全国独家）、注 射用盐酸克林霉素磷酸酯、注射用单磷酸阿糖腺苷、注射用更昔洛韦、复方柳唑气雾剂（全国独家）和 伏立康唑片、医用透明 ...

7月2日，昭衍新药今日收盘21.95元，下跌1.57%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到42.46倍，总市值164.51亿元。 从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均41.66倍，行业中值43.69倍，昭衍新药排 名第29位。 来源：金融界 北京昭衍新药研究中心股份有限公司的主营业务是从事以药物非临床安全性评价服务为主的药物临床前 研究服务和实验动物及附属产品的销售业务。公司的主要产品是药物非临床研究服务、临床服务及其 他、实验模型供应。 最新一期业绩显示，2025年一季报，公司实现营业收入2.87亿元，同比-11.54%；净利润4111.95万元， 同比115.11%，销售毛利率28.61%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13昭衍新药42.46222.082.03164.51亿行业平均 41.6648.643.54162.93亿行业中值43.6957.422.7258.39亿1药明康德18.0321.343.232016.30亿2康龙化成 23.3224.293.10435.66亿3诺泰生物23.8528.944.26117.05亿4普蕊 ...